Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just go to ihub news section and look for "Statement of Changes in Beneficial Ownership"
You will see two of those for every month.
There is no way a an Immuno-Oncology biotech (ADXS) should be trader near cash value:
1. in a phase 3 trail with SPA, Fast Track and Orphan Drug,
2. four cancer franchises
3. ADXS-NEO franchise with the backing of AMGN ($500 Million)
4. ADXS-PSA confirmed for ASCO 2018
5. PETX AT-014 already in market (proof that ADXS LM tech is legit)
6. EU Application Filed
Lol hang in there.
The way I see it, ADXS is trading near cash value... that alone is a reason to continue to hold.
In theory, if everything was 100% wrong (which is not the case) with ADXS, even then it should trade near 3 to 5 times its cash value....
ADXS will realize its fair value eventually.
I wouldn't get my hopes high on CEO/CMO.... Tony said the same things during December earnings conference (although he didn't give a definitive target timeline like mid 2018 before, going by memory)
With 1+ million daily volume at close every day, ADXS price should be flying high.... this high volume is very confusing
Jefferies Group Raises Advaxis Q2 2018 Earnings Estimates to ($0.42) EPS (Previously ($0.55))
https://www.americanbankingnews.com/2018/03/15/q2-2018-earnings-estimate-for-advaxis-inc-adxs-issued-by-jefferies-group.html
Thanks GangstaKitty, you're a class above genius... and I'm not smart enough to know that word....
-_-'
Thanks Edward, you're a genius
"I think that's highly likely, but that doesn't undermine ADXS's approach. It's not like ADXS is developing a competitor; it's a separate treatment option."
I think ADXS phase 3 is brilliantly designed as to prevent recurrence... with that, ADXS would really be supporting other drugs and shouldn't have any competitor...
So do you MERK will beat ADXS in getting cervical treatment to market?
"Holding forever made ADXS shareholder lost 95% too. LOL"
Over two years ... and there is a possibility of recovery because fundamentals are strong...
Blindly jumping in and out... one could lose 95% in two months and there is no reasoning for recovery
"no body on this board talk about the potential of Phase 3 AIM2CERV study.
any insights on that study?"
Dew and hovacre have been indirectly talking about this for the past few days....
While you guys are focused on patient's death.... the real news is MERK getting priority review from FDA on cervical cancer
What happened to OWCP? I been gone a few months... how did it fall from 0.50s to 0.20s?
Patient death, lowered price target and ADXS is green today?
Am I dreaming? *pinches self.... nope I'm awake LOL
Jokes aside, this is proof that the tide is about to turn for...
It is important ADXS Management must have their game face during the annual day....
"I couldn’t help myself. I sold another to buy more and lowered my avg cost by 0.75."
Yea, same here. When I get new (paycheck) money to invest, I look at everything else (which is way overvalued) and then I look at ADXS (which is an extreme case of undervalue), and then I can't help myself even though conventional wisdom is to diversify....
"They are most likely factoring in another dilution since TL said 13 months for EMA decision. If 13 months is correct, another dilution will happen by end of 2018."
But what about:
1. $500 Million AMGN partnership money?
2. EU Partnership deal to accelerate now that application is filed
What do you think of the theory of delayed IND of ADXS-NEO as speculation of possible buyout of ADXS by AMGN? (Not my idea, someone posted before)
CEO target has been set for mid 2018 which contradicts the speculation above...
But I still don't understand why it can take 2 months to get an IND approved from FDA and take 1+ year to still not resubmit modified IND?
"What is the key for hold to happen?"
The key to hold is that it happened during or right after dosing... making it the culprit
"It will be interesting to see if they step up and use their size and leverage with the FDA to help get the hold resolved quickly or if they have so many collaborations with other small partners they just move on leaving ADXS twisting in the wind."
Since ADXS is running the trail, I don't think AZN will bother stepping in...
Also, AZN already made a deal with some other company which Dew mentioned is a clear signal and AZN has no future with ADXS....
It's probably best to just close this trail altogether as it's a money pit and AZN drug combo has worse results than ADXS mono....
Someone bought 100,000 ADXS shares in one shot 11:49:36
Crazy volume today... if anything, we got buying interest popping up
"The patient who died had advanced refractory metastatic cervical cancer that progressed following treatment with other therapies. After entering the trial about one year ago, the patient received six combination cycles—11 doses of listeria-based cancer vaccine axalimogene filolisbac and 21 hits of Imfinzi. The first five cycles passed without incident. That changed with the most recent round of treatment.
Medical problems began following the first dose of Imfinzi but were managed, Advaxis CSO Robert Petit said on a call with investors. The patient then received a second dose of Imfinzi followed by an administration of axalimogene filolisbac. The situation escalated from there.
After receiving treatment for hypotension, the patient was hospitalized and thereafter developed respiratory failure. Efforts to stop the worsening of the patient’s condition fell short and she died.
The events leave Advaxis facing the conundrum of why a patient who had previously tolerated both drugs died of respiratory failure. Prior studies suggest Imfinzi may be the culprit. One patient had died of respiratory failure in AstraZeneca’s phase 3 trial of Imfinzi in lung cancer at the time it reported data in September, and analysts at Jefferies uncovered other incidents linked to the drug and checkpoint inhibitors in general.
"We reviewed the BLA for [Imfinzi] and noted 0.8% death rate within 30 days due to respiratory failure in the safety database. This also corresponds with SAE reports of 1% respiratory failure in trials for [Imfinzi], [Keytruda] and [Bavencio] that we reviewed, suggesting 1% incidence across most PD-1/L1s. In some cases, the SAEs were reported as [cardiorespiratory] arrest, which suggests cardiac etiology and would also align with hypotension as reported for the deceased patient [in Advaxis' trial]," the analysts wrote."
Here is some more confirmation that Imfinzi could be the culprit:
"Medical problems began following the first dose of Imfinzi but were managed, Advaxis CSO Robert Petit said on a call with investors. "
Source:
https://www.fiercebiotech.com/biotech/fda-hits-advaxis-clinical-hold-after-death-astrazeneca-combination-trial
What do you think of Petit implying that:
The patient received a dose of durvalumab in the morning and then she wasn't feeling well and then ADXS dose got applied afterwards and then the complications started?
I heard the recording last night, so going by memory that this is what I heard....
Key take aways from the conference
1.Tony's quote:
"We remain committed to our mission to advance our LM technology....AND CREATE SUBSTANTIAL SHAREHOLDER VALUE."
2. ADXS-PSA confirmed as presentation at ASCO (already submitted to ASCO)
3. Patient who died was been treated for over a year with 21 durvalumab doses and 11 AXAL doses. To date, ADXS LM has been used safely on over 250 patients with over 700 doses.
Thanks for the link Dew!
Anyone got a link for ADXS conference call recording? The link posted on ADXS website is Nkrumah working
Yep, the only thing ADXS Management has to do is make some progress and only way is up as ADXS is priced at near cash on hand...
"Any bets on what happens Monday? Anyone??"
Uhhh... ADXS Management disappoints again as usual and shorties tell themselves what the heck were they thinking and go back to shorting ADXS??
Lol, Just kidding, I am hopeful that if not on Monday, sometime before or around the annual day we will get something good.... and the reason I am hopeful are the short numbers telling the market that the tide is turning....
"Short Interest down to 5 million, that's very good positive"
Indeed that's a very good positive...
My only hope is for short interest to remain low and that it's not a One time deal....
My worry is that daily short interest volume tumbled from mid to end of February... but started climbing again in March...
But that's the data reported to FINRA... it must have some legitimacy
"Interesting we see the same data however I see a trend pointing downward. "
Who is we? And what is the like to your data?
Ok, thanks gajj
According to Nasdaq website, Earnings Report is coming tonight...
https://m.nasdaq.com/earnings/report/adxs
Check out the daily short interest volume graph on link below....
It seems daily short volume tumbled from mid to end of February and is now picking back up in March....
http://www.volumebot.com/?s=adxs
MARK YOUR CALENDARS WITH FOLLOWING DATES!
3/12/18
Earnings Report and Conference Call
3/12/18 - 3/15/18
Barclays Global Healthcare Conference
3/21/18
Annual Meeting and proxy statements and PITCH FORKS and stuff
3/23/8 - 3/27/8
Keystone Symposia on Cancer Immunotherapies: ADXS has 3 poster presentations
What do you guys think of ADXS LM combination with a gene therapy such as CRISPR?
listed below is a tweet I am borrowing:
"$Adxs #Advaxis brought back to just $100M can make a BIG comeback ON partnering for delivery application, possibly #GeneTherapy and other noble therapies in need for noble delivery paths. $ADRO $NTLA $EDIT $CRISP #IMMUNOTHERAPY $CELG $MRK better act now #CRISPR"
"Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018"
Daily Volume over 1 million these days could be hint that something of material could be expected from the Earnings Report....
However, Daily Volume over 1 million these days with not enough price rise could be hinting that don't expect a price rise.....
"Jefferies may have shorted shares above 2 the last few days and will cover when they exercise the option at 2"
But according to 13-F, Jeffries has been buying ADXS like crazy months before the dilution
Yep, they sure have been acting like that performance wise.
"Need some volume/stability at current level and some spikes on news."
Volume - CHECK
Stability- CHECK
Price Spike on news - LOADING...
DO NOT TURN OFF THE PC WHILE LOADING OR ALL CHANGES WILL BE LOST...
*ADXS Management turns off the PC